Home › NDC Lookup › RxCUI directory › RxCUI 1368398

Alogliptin 12.5 MG / metformin hydrochloride 500 MG Oral Tablet [Kazano] — RxCUI 1368398

RxNorm drug concept · Semantic branded drug
RxCUI 1368398 Semantic branded drug · SBD ● Current RxNorm concept 2 FDA products 8 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1368398
Official nameAlogliptin 12.5 MG / metformin hydrochloride 500 MG Oral Tablet [Kazano]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asKazano 12.5/500 Oral Tablet; Kazano 12.5 MG / 500 MG Oral Tablet; Kazano 12.5/500 (as alogliptin benzoate 17 MG / metformin hydrochloride) Oral Tablet
FDA products mapped2
Package NDCs mapped8
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Alogliptin: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • After you eat, your gut releases natural hormones that signal your pancreas to release insulin. An enzyme in your body called DPP-4 normally destroys those hormones within minutes....
  • What exactly does alogliptin do — how does it lower my blood sugar?
  • It depends on how well your kidneys are working. Since alogliptin is mostly cleared through the kidneys, your prescriber will likely lower your dose if your kidney function is redu...
  • Can I take alogliptin if I have kidney problems?
📖 Read our full Alogliptin guide →

🕸️ Concept Web — How Alogliptin 12.5 MG / metformin hydrochloride 500... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Alogliptin 12.5 MG / metformin hydrochloride 500 MG Oral Tablet [Kazano] RxCUI 1368398

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 4

    The active substance itself — no strength, form, or brand attached yet.

    • Alogliptin 1368001
    • Metformin 6809
    • Alogliptin / metformin 1368384
    • Metformin hydrochloride 235743
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Kazano 1372692
  3. Dose forms 13

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Alogliptin / metformin Oral Tablet 1368383
    • Alogliptin / metformin hydrochloride Oral Tablet 2647239
    • Alogliptin / metformin Oral Product 1368381
    • Alogliptin / metformin Pill 1368382
    • Alogliptin / metformin hydrochloride Oral Product 2663139
    • Alogliptin / metformin hydrochloride Pill 2662620
    • Alogliptin / metformin Oral Tablet [Kazano] 1368395
    • Alogliptin / metformin hydrochloride Oral Tablet [Kazano] 2658568
    • +5 more in this family
  4. Clinical & branded drugs 4

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 17 of 22 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Alogliptin 12.5 MG / metformin hydrochloride 500 MG Oral Tablet SCD · 1368392
  • Alogliptin 12.5 MG SCDC · 1368033
  • Metformin hydrochloride 500 MG SCDC · 860974
  • Alogliptin / metformin Oral Tablet SCDF · 1368383
  • Alogliptin / metformin hydrochloride Oral Tablet SCDFP · 2647239
  • Alogliptin / metformin Oral Product SCDG · 1368381
  • Alogliptin / metformin Pill SCDG · 1368382
  • Alogliptin / metformin hydrochloride Oral Product SCDGP · 2663139
  • Alogliptin / metformin hydrochloride Pill SCDGP · 2662620

Brand-Name Concepts

  • Alogliptin 12.5 MG / metformin hydrochloride 500 MG [Kazano] SBDC · 1368394
  • Alogliptin / metformin Oral Tablet [Kazano] SBDF · 1368395
  • Alogliptin / metformin hydrochloride Oral Tablet [Kazano] SBDFP · 2658568
  • Kazano Oral Product SBDG · 1368396
  • Kazano Pill SBDG · 1368397
  • Kazano BN · 1372692

📦 FDA Products & Package NDCs

2 products · 8 package NDCs
8 package NDCs map to RxCUI 1368398 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
64764-0335-01 4 CARTON in 1 TRAY (64764-335-01) / 1 BLISTER PACK in 1 CAR... KAZANO Takeda Pharmaceuticals America, Inc. 2013-01-25
64764-0335-60 60 TABLET, FILM COATED in 1 BOTTLE (64764-335-60) KAZANO Takeda Pharmaceuticals America, Inc. 2013-01-25
64764-0335-77 500 TABLET, FILM COATED in 1 BOTTLE (64764-335-77) KAZANO Takeda Pharmaceuticals America, Inc. 2013-01-25
64764-0335-80 180 TABLET, FILM COATED in 1 BOTTLE (64764-335-80) KAZANO Takeda Pharmaceuticals America, Inc. 2013-01-25
64764-0337-01 4 CARTON in 1 TRAY (64764-337-01) / 1 BLISTER PACK in 1 CAR... KAZANO Takeda Pharmaceuticals America, Inc. 2013-01-25
64764-0337-60 60 TABLET, FILM COATED in 1 BOTTLE (64764-337-60) KAZANO Takeda Pharmaceuticals America, Inc. 2013-01-25
64764-0337-77 500 TABLET, FILM COATED in 1 BOTTLE (64764-337-77) KAZANO Takeda Pharmaceuticals America, Inc. 2013-01-25
64764-0337-80 180 TABLET, FILM COATED in 1 BOTTLE (64764-337-80) KAZANO Takeda Pharmaceuticals America, Inc. 2013-01-25
Observed labelers: Takeda Pharmaceuticals America, Inc. (8) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.